Conceivable Life Sciences: Company Profile

Background

Conceivable Life Sciences is a biotechnology company headquartered in New York City, specializing in revolutionizing fertility care through the automation of in vitro fertilization (IVF) laboratories. Founded in 2022, the company integrates artificial intelligence (AI) and robotics to automate over 200 intricate steps involved in embryo creation, including delicate single-cell procedures like intracytoplasmic sperm injection (ICSI). This innovation aims to enhance precision, quality, and scalability in IVF processes, addressing the global demand for accessible and affordable reproductive care.

Key Strategic Focus

Conceivable's strategic focus centers on the development and commercialization of AURA, the world's first AI-powered automated IVF lab. AURA automates the entire IVF lab process, encompassing dish preparation, sperm processing, egg discovery and preparation, ICSI, incubation, vitrification, and thawing. By leveraging AI, robotics, advanced optics, and machine vision, AURA aims to standardize IVF procedures, improve success rates, and reduce costs, thereby making fertility treatments more accessible to a broader population.

Financials and Funding

As of September 2025, Conceivable Life Sciences has raised a total of $70 million in funding over multiple rounds. The most recent funding round, a $50 million Series A, was led by Advance Venture Partners (AVP), with participation from existing investors such as ARTIS Ventures, Stride, and ACME. This capital supports the company's mission to make IVF more accessible, scalable, and effective at delivering improved pregnancy results.

Pipeline Development

Conceivable is currently conducting a 100-patient Institutional Review Board (IRB) study as part of its commercial pilot program in Mexico City. In a prior IRB-approved proof-of-concept study using AURA prototypes, 21 pregnancies were achieved, demonstrating success rates comparable to top-performing fertility clinics. These studies are critical steps toward validating the efficacy and safety of the automated IVF platform ahead of broader commercialization.

Technological Platform and Innovation

Conceivable's AURA platform represents a significant technological advancement in reproductive medicine. Key innovations include:

Proprietary Technologies: AURA integrates six automated workstations that perform all essential IVF lab functions, such as dish preparation, sperm processing, egg discovery and preparation, ICSI, incubation, vitrification, and thawing.

Scientific Methods: The platform employs advanced optics and machine vision to perform precise single-cell surgeries, enhancing the accuracy and consistency of procedures like ICSI.

AI-Driven Capabilities: AI algorithms are utilized for tasks such as sperm selection and embryo classification, aiming to improve success rates and reduce human error.

Leadership Team

Conceivable's leadership comprises a multidisciplinary team with extensive experience in embryology, automation, AI, and robotics:

Alan Murray: Co-founder and Chief Executive Officer, bringing a background in leading innovative startups.

Joshua Abram: Co-founder and Chairman, with a history of successful ventures across various industries.

Dr. Alejandro Chavez-Badiola: Co-founder and Chief Medical Officer, a reproductive endocrinologist instrumental in developing the company's medical technologies.

Dr. Jacques Cohen: Chief Scientific Officer, renowned for his contributions to embryology and reproductive science.

Dr. Stephanie Kuku: Chief Knowledge Officer, overseeing the integration of scientific research and clinical practice.

Ann Watson: Chief Marketing Officer, leading the company's marketing and communication strategies.

The leadership team is supported by experts in engineering, data science, and product development, collectively driving Conceivable's mission forward.

Market Insights and Competitor Analysis

The global fertility market is experiencing significant growth, driven by increasing infertility rates and advancements in reproductive technologies. Despite this growth, access to IVF remains limited due to high costs and the manual nature of existing processes. Conceivable's automation technology positions it to address these challenges by offering scalable and cost-effective solutions.

Key competitors in the fertility technology space include:

TMRW Life Sciences: Specializes in automated cryostorage solutions for eggs and embryos, focusing on improving the safety and efficiency of specimen storage.

Overture Life: Develops technologies to modernize IVF processes through engineering, reproductive medicine, and regulatory-grade validation.

While these companies contribute to advancements in fertility care, Conceivable's end-to-end automation of the IVF lab distinguishes it by addressing the entire laboratory process, potentially offering greater scalability and cost reductions.

Strategic Collaborations and Partnerships

Conceivable has established partnerships with leading venture capital firms and healthcare investors, including ARTIS Ventures, ACME Capital, and Atlantic Health Venture Studio. These collaborations provide not only financial support but also strategic guidance and industry expertise, bolstering the company's efforts to innovate and expand its market presence.

Operational Insights

By automating the IVF lab, Conceivable aims to achieve several operational advantages:

Precision: Automation reduces human error, enhancing the accuracy of delicate procedures.

Traceability: Digital tracking of specimens ensures safety and accountability throughout the IVF process.

Scalability: Automated systems can handle increased volumes, addressing the growing demand for IVF services.

Cost Reduction: Operational efficiencies lead to lower costs, making IVF more accessible to a broader population.

Strategic Opportunities and Future Directions

Conceivable is poised to capitalize on several strategic opportunities:

U.S. Market Entry: Preparations are underway for a U.S. launch in early 2026, expanding the company's reach and impact.

Technology Refinement: Ongoing research and development efforts aim to further enhance the AURA platform's capabilities and success rates.

Global Expansion: Beyond the U.S., Conceivable plans to introduce its technology to other international markets, addressing the global need for accessible fertility treatments.

Collaborative Research: Partnerships with academic and clinical institutions will support continuous innovation and validation of the company's technologies.